Atomoxetine -SIL NDSRI
References
FAQ's
References
- Foster, Bennie Joe; Lavagnino, Edward Ralph, 3-aryloxy-3-phenylpropylamines, EP52492, May 26, 1982, Eli Lilly and Co., United States
- Zhu, Hao-Jie; Wang, Jun-Sheng; Donovan, Jennifer L.; DeVane, C. Lindsay; Gibson, Bryan B.; Markowitz, John S., Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 846, Issue: 1-2, Pages: 351-354, 2007, DOI: (10.1016/j.jchromb.2006.08.019)
Frequently Asked Questions
What is the role of impurity profiling in the synthesis of Atomoxetine?
Impurity profiling helps understand the nature and quantity of impurities in pharmaceuticals, which is crucial for the safety and efficacy of the drug.
What are the steps to take if the level of impurities in Atomoxetine exceeds the acceptable limit?
If the level of impurities in Atomoxetine exceeds the acceptable limit, the particular batch is discarded, and an investigation identifies the source of the impurities.
How is an unknown impurity in Atomoxetine identified?
An unknown impurity identification is possible using the HPLC technique during the commercial synthesis of Atomoxetine.
What are the uses of Atomoxetine impurities reference standards?
Atomoxetine impurities reference standards can help in pharmaceutical research, product development, ANDA and DMF filing, quality control (QC), method validation, and stability studies.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.